Pomdoctor Limited
POMHealthcareNASDAQPharmaceutical Retailers · Last scanned Oct 26, 2026
Scan Results
Daily timeframePomdoctor Limited, through its subsidiaries, offers an online B2C portal to sell pharmaceutical products. The company carries a $10.8M market cap, placing it firmly in the micro-cap category. The company develops an online medical services platform for chronic diseases in China.
Market Cap
$10.8M
Beta
—
P/E (TTM)
—
P/E (Fwd)
—
EPS (TTM)
$-40.31
EPS (Fwd)
—
ROE
—
ROA
-352.1%
Cash
$12.6M
Total Debt
$450.1M
Free CF
$4.1M
52W Change
-98.6%
Annual Financials
Cash vs Debt
Where POM stands vs its 150-day and 200-day moving averages
As of the October 14, 2026 close, POM finished 72.08% below its 150-day moving average ($2.65) and 77.02% below its 200-day moving average ($3.22). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is POM overbought or oversold?
At the October 14, 2026 close, POM's RSI(14) was 47.6, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $12.6M in cash, though total debt stands at $450.1M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow comes in at $4.1M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Revenue has grown from $215.4M (2021) to $399.9M (2025), reflecting a 86% increase over the period.
The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Pomdoctor Limited's trajectory.